Pfizer Deferred Tax Assets and Other Non-Current Assets increased by 2.1% to $9.83B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.1%, from $9.85B to $9.83B. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets and Other Non-Current Assets shows an upward trend with a 14.6% CAGR.
An increase generally reflects a growing long-term asset base or deferred tax position, while a decrease suggests asset liquidation or tax benefit utilization.
This is the aggregate balance of non-current deferred tax assets and other miscellaneous non-current assets not classifi...
Commonly found in the non-current asset section of balance sheets for large, diversified financial firms.
deferred_tax_assets_other_noncurrent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.06B | $6.71B | $7.68B | $7.88B | $7.66B | $10.89B | $13.16B | $12.97B | $13.03B | $8.81B | $12.47B | $11.20B | $10.71B | $10.49B | $9.82B | $9.85B | $9.46B | $9.32B | $9.63B | $9.83B |
| QoQ Change | — | +10.7% | +14.5% | +2.6% | -2.8% | +42.2% | +20.9% | -1.5% | +0.5% | -32.4% | +41.6% | -10.2% | -4.3% | -2.1% | -6.4% | +0.3% | -4.0% | -1.5% | +3.4% | +2.1% |
| YoY Change | — | — | — | — | +26.5% | +62.4% | +71.4% | +64.6% | +70.1% | -19.1% | -5.3% | -13.6% | -17.8% | +19.1% | -21.3% | -12.1% | -11.7% | -11.1% | -1.9% | -0.1% |